{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T18:30:26Z","timestamp":1791311426037,"version":"4.3.1"},"reference-count":37,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"vor","delay-in-days":1461,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1038\/ki.2013.253","type":"journal-article","created":{"date-parts":[[2013,6,26]],"date-time":"2013-06-26T12:39:12Z","timestamp":1372250352000},"page":"182-190","source":"Crossref","is-referenced-by-count":40,"title":["Maintaining calcineurin inhibition after the diagnosis of post-transplant lymphoproliferative disorder improves renal graft survival"],"prefix":"10.1016","volume":"85","author":[{"given":"Jean-Emmanuel","family":"Serre","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Michonneau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Bachy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laure-H\u00e9l\u00e8ne","family":"No\u00ebl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Dubois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Suberbielle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henri","family":"Kreis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Legendre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-France","family":"Mamzer-Bruneel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Morelon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Thaunat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1038\/ki.2013.253_bb0010","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1111\/j.1600-6143.2011.03896.x","article-title":"Epidemiology of posttransplant lymphoproliferative disorders in adult kidney and kidney pancreas recipients: report of the French registry and analysis of subgroups of lymphomas","volume":"12","author":"Caillard","year":"2012","journal-title":"Am J Transplant"},{"key":"10.1038\/ki.2013.253_bb0015","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1200\/JCO.2012.43.2344","article-title":"Post-transplantation lymphoproliferative disorder after kidney transplantation: report of a nationwide French registry and the development of a new prognostic score","volume":"31","author":"Caillard","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1038\/ki.2013.253_bb0020","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S0140-6736(84)90994-2","article-title":"Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy","volume":"1","author":"Starzl","year":"1984","journal-title":"Lancet"},{"key":"10.1038\/ki.2013.253_bb0025","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1093\/infdis\/152.5.876","article-title":"Epstein-Barr virus infections and DNA hybridization studies in posttransplantation lymphoma and lymphoproliferative lesions: the role of primary infection","volume":"152","author":"Ho","year":"1985","journal-title":"J Infect Dis"},{"key":"10.1038\/ki.2013.253_bb0030","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1056\/NEJMra032015","article-title":"Persistence of the Epstein-Barr virus and the origins of associated lymphomas","volume":"350","author":"Thorley-Lawson","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1038\/ki.2013.253_bb0035","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1146\/annurev.pathol.1.110304.100209","article-title":"Spectrum of Epstein-Barr virus-associated diseases","volume":"1","author":"Kutok","year":"2006","journal-title":"Annu Rev Pathol"},{"key":"10.1038\/ki.2013.253_bb0040","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.2165\/11635690-000000000-00000","article-title":"Managing post-transplant lymphoproliferative disorders in solid-organ transplant recipients: a review of immunosuppressant regimens","volume":"72","author":"Murukesan","year":"2012","journal-title":"Drugs"},{"key":"10.1038\/ki.2013.253_bb0045","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/TP.0b013e3181761659","article-title":"Prospective study of sequential reduction in immunosuppression, interferon alpha-2B, and chemotherapy for posttransplantation lymphoproliferative disorder","volume":"86","author":"Swinnen","year":"2008","journal-title":"Transplantation"},{"key":"10.1038\/ki.2013.253_bb0050","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1097\/00007890-200104270-00012","article-title":"Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: analysis of prognostic variables and long-term follow-up of 42 adult patients","volume":"71","author":"Tsai","year":"2001","journal-title":"Transplantation"},{"key":"10.1038\/ki.2013.253_bb0055","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/j.1600-6143.2010.03387.x","article-title":"Reduction of immunosuppression as initial therapy for posttransplantation lymphoproliferative disorder(bigstar)","volume":"11","author":"Reshef","year":"2011","journal-title":"Am J Transplant"},{"key":"10.1038\/ki.2013.253_bb0060","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1053\/j.ajkd.2011.07.015","article-title":"Lymphoproliferative disorders after adult kidney transplant: epidemiology and comparison of registry report with claims-based diagnoses","volume":"58","author":"Kasiske","year":"2011","journal-title":"Am J Kidney Dis"},{"key":"10.1038\/ki.2013.253_bb0065","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1111\/j.1365-2141.2010.08161.x","article-title":"Diagnosis of post-transplant lymphoproliferative disorder in solid organ transplant recipients - BCSH and BTS Guidelines","volume":"149","author":"Parker","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1038\/ki.2013.253_bb0070","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1097\/00007890-199911270-00015","article-title":"Epstein-Barr virus-induced posttransplant lymphoproliferative disorders. ASTS\/ASTP EBV-PTLD Task Force and The Mayo Clinic Organized International Consensus Development Meeting","volume":"68","author":"Paya","year":"1999","journal-title":"Transplantation"},{"issue":"Suppl 4","key":"10.1038\/ki.2013.253_bb0075","first-page":"31","article-title":"European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. 6.1 Post-transplant lymphoproliferative disease (PTLD): prevention and treatment","volume":"17","author":"EBPG Expert Group on Renal Transplantation","year":"2002","journal-title":"Nephrol Dial Transplant"},{"key":"10.1038\/ki.2013.253_bb0080","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1097\/01.TP.0000120181.89206.54","article-title":"Pro- and anti-cancer effects of immunosuppressive agents used in organ transplantation","volume":"77","author":"Guba","year":"2004","journal-title":"Transplantation"},{"key":"10.1038\/ki.2013.253_bb0085","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.nephro.2005.01.003","article-title":"[Cancer and immunosuppression: pro- and antitumoral effects of immunosuppressive drugs]","volume":"1","author":"Thaunat","year":"2005","journal-title":"Nephrol Ther"},{"key":"10.1038\/ki.2013.253_bb0090","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1097\/01.TP.0000063934.89714.19","article-title":"Immunosuppressive TOR kinase inhibitor everolimus (RAD) suppresses growth of cells derived from posttransplant lymphoproliferative disorder at allograft-protecting doses","volume":"75","author":"Majewski","year":"2003","journal-title":"Transplantation"},{"key":"10.1038\/ki.2013.253_bb0095","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.smim.2011.09.002","article-title":"Chronic alloantibody mediated rejection","volume":"24","author":"Smith","year":"2012","journal-title":"Semin Immunol"},{"key":"10.1038\/ki.2013.253_bb0100","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.trim.2011.11.003","article-title":"Humoral immunity in chronic allograft rejection: puzzle pieces come together","volume":"26","author":"Thaunat","year":"2012","journal-title":"Transpl Immunol"},{"key":"10.1038\/ki.2013.253_bb0105","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1097\/TP.0b013e3182483713","article-title":"A personal perspective: 100-year history of the humoral theory of transplantation","volume":"93","author":"Terasaki","year":"2012","journal-title":"Transplantation"},{"key":"10.1038\/ki.2013.253_bb0110","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1097\/TP.0b013e31819004a1","article-title":"Comparison of the predictive performance of eGFR formulae for mortality and graft failure in renal transplant recipients","volume":"87","author":"He","year":"2009","journal-title":"Transplantation"},{"key":"10.1038\/ki.2013.253_bb0115","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1093\/ndt\/gfm708","article-title":"Estimated glomerular filtration rate as an end point in kidney transplant trial: where do we stand?","volume":"23","author":"Mariat","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"10.1038\/ki.2013.253_bb0120","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1080\/08830180902929404","article-title":"Clinical relevance of immune monitoring in solid organ transplantation","volume":"28","author":"Daniel","year":"2009","journal-title":"Int Rev Immunol"},{"key":"10.1038\/ki.2013.253_bb0125","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1111\/j.1440-1797.2010.01349.x","article-title":"Review: Pharmacodynamic monitoring of immunosuppression in kidney transplantation","volume":"15","author":"Barraclough","year":"2010","journal-title":"Nephrology (Carlton)"},{"key":"10.1038\/ki.2013.253_bb0130","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1067\/mlc.2001.111469","article-title":"Effect of cyclosporin A on DNA repair and cancer incidence in kidney transplant recipients","volume":"137","author":"Herman","year":"2001","journal-title":"J Lab Clin Med"},{"key":"10.1038\/ki.2013.253_bb0135","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.mehy.2004.03.030","article-title":"Molecular effects of cyclosporine and oncogenesis: a new model","volume":"63","author":"Andre","year":"2004","journal-title":"Med Hypotheses"},{"key":"10.1038\/ki.2013.253_bb0140","doi-asserted-by":"crossref","first-page":"3956","DOI":"10.1182\/blood.V84.11.3956.bloodjournal84113956","article-title":"Interleukin-6 and Epstein-Barr virus induction by cyclosporine A: potential role in lymphoproliferative disease","volume":"84","author":"Tanner","year":"1994","journal-title":"Blood"},{"key":"10.1038\/ki.2013.253_bb0145","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1097\/00007890-199001000-00042","article-title":"Possible association of the immunosuppressive and B cell lymphoma-promoting properties of cyclosporine","volume":"49","author":"Walz","year":"1990","journal-title":"Transplantation"},{"key":"10.1038\/ki.2013.253_bb0150","first-page":"2211","article-title":"Cancers following cyclosporine therapy","volume":"19","author":"Penn","year":"1987","journal-title":"Transplant Proc"},{"key":"10.1038\/ki.2013.253_bb0155","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1097\/01.tp.0000179639.98338.39","article-title":"Posttransplant lymphoproliferative disorders after renal transplantation in the United States in era of modern immunosuppression","volume":"80","author":"Caillard","year":"2005","journal-title":"Transplantation"},{"key":"10.1038\/ki.2013.253_bb0160","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1046\/j.1600-6143.2003.00325.x","article-title":"Lymphomas after solid organ transplantation: a collaborative transplant study report","volume":"4","author":"Opelz","year":"2004","journal-title":"Am J Transplant"},{"key":"10.1038\/ki.2013.253_bb0165","doi-asserted-by":"crossref","first-page":"3622","DOI":"10.1200\/JCO.2000.18.21.3622","article-title":"Durable remission after aggressive chemotherapy for very late post-kidney transplant lymphoproliferation: a report of 16 cases observed in a single center","volume":"18","author":"Mamzer-Bruneel","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1038\/ki.2013.253_bb0170","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1111\/j.1600-6143.2009.02772.x","article-title":"Treatment of PTLD with rituximab and CHOP reduces the risk of renal graft impairment after reduction of immunosuppression","volume":"9","author":"Trappe","year":"2009","journal-title":"Am J Transplant"},{"key":"10.1038\/ki.2013.253_bb0175","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1093\/ndt\/gfs476","article-title":"Late-onset post-transplantation lymphoproliferative disorders after kidney transplantation: a monocentric study over three decades","volume":"28","author":"Michonneau","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"10.1038\/ki.2013.253_bb0180","series-title":"Classification of Tumours of Haematopoietic and Lymphoid Tissues","first-page":"342","article-title":"WHO classification of post-transplant lymphoproliferative disorders","author":"Swerdlow","year":"2008"},{"key":"10.1038\/ki.2013.253_bb0185","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1111\/j.1600-6143.2008.02159.x","article-title":"Banff 07 classification of renal allograft pathology: updates and future directions","volume":"8","author":"Solez","year":"2008","journal-title":"Am J Transplant"},{"key":"10.1038\/ki.2013.253_bb0190","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1111\/j.1600-6143.2011.03931.x","article-title":"A new diagnostic algorithm for antibody-mediated microcirculation inflammation in kidney transplants","volume":"12","author":"Sis","year":"2012","journal-title":"Am J Transplant"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253815561383?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253815561383?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,7,29]],"date-time":"2020-07-29T04:48:00Z","timestamp":1595998080000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253815561383"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["S0085253815561383"],"URL":"https:\/\/doi.org\/10.1038\/ki.2013.253","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2014,1]]}}}